|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: New hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar
|
|
7
|
Zhang L, Nakaya K, Yoshida T and Kuroiwa
Y: Induction by bufalin of differentiation of human leukemia cells
HL60, U937, and ML1 toward macrophage/monocyte-like cells and its
potent synergistic effect on the differentiation of human leukemia
cells in combination with other inducers. Cancer Res. 52:4634–4641.
1992.PubMed/NCBI
|
|
8
|
Jing Y, Watabe M, Hashimoto S, Nakajo S
and Nakaya K: Cell cycle arrest and protein kinase modulating
effect of bufalin on human leukemia ML1 cells. Anticancer Res.
14(3A): 1193–1198. 1994.PubMed/NCBI
|
|
9
|
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang
PS: Apoptotic signaling in bufalin- and cinobufagin-treated
androgen-dependent and -independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng
Y, Zhang J and Liu Y: PI3K/Akt is involved in bufalin-induced
apoptosis in gastric cancer cells. Anticancer Drugs. 20:59–64.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qi F, Inagaki Y, Gao B, Cui X, Xu H,
Kokudo N, Li A and Tang W: Bufalin and cinobufagin induce apoptosis
of human hepatocellular carcinoma cells via Fas- and
mitochondria-mediated pathways. Cancer Sci. 102:951–958. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Qu X, Wang P, Tian X, Luo Y, Liu S
and Lu X: WT1 down-regulation during K562 cell differentiation and
apoptosis induced by bufalin. Zhonghua Xue Ye Xue Za Zhi.
23:356–359. 2002.PubMed/NCBI
|
|
13
|
Qu X, Liu Y, Ma Y, Zhang Y, Li Y and Hou
K: Up-regulation of the Cbl family of ubiquitin ligases is involved
in ATRA and bufalin-induced cell adhesion but not cell
differentiation. Biochem Biophys Res Commun. 367:183–189. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu Z, Sun H, Ma G, Wang Z, Li E and Liu Y
and Liu Y: Bufalin induces lung cancer cell apoptosis via the
inhibition of PI3K/Akt pathway. Int J Mol Sci. 13:2025–2035. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang ZJ, Yang YK and Wu WZ: Bufalin
attenuates the stage and metastatic potential of hepatocellular
carcinoma in nude mice. J Transl Med. 12:572014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qiu DZ, Zhang ZJ, Wu WZ and Yang YK:
Bufalin, a component in Chansu, inhibits proliferation and invasion
of hepatocellular carcinoma cells. BMC Complement Altern Med.
13:1852013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chueh FS, Chen YY, Huang AC, Ho HC, Liao
CL, Yang JS, Kuo CL and Chung JG: Bufalin-inhibited migration and
invasion in human osteosarcoma U-2 OS cells is carried out by
suppression of the matrix metalloproteinase-2, ERK, and JNK
signaling pathways. Environ Toxicol. 29:21–29. 2014. View Article : Google Scholar
|
|
18
|
Moustakas A and Heldin CH: Induction of
epithelial-mesen-chymal transition by transforming growth factor β.
Semin Cancer Biol. 22:446–454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu J, Lamouille S and Derynck R:
TGF-β-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang YE: Non-Smad pathways in TGF-β
signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar :
|
|
22
|
Kim JH, Jang YS, Eom KS, Hwang YI, Kang
HR, Jang SH, Kim CH, Park YB, Lee MG, Hyun IG, et al: Transforming
growth factor β1 induces epithelial-to-mesenchymal transition of
A549 cells. J Korean Med Sci. 22:898–904. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ellenrieder V, Hendler SF, Boeck W,
Seufferlein T, Menke A, Ruhland C, Adler G and Gress TM:
Transforming growth factor β1 treatment leads to an
epithelial-mesenchymal transdifferentiation of pancreatic cancer
cells requiring extracellular signal-regulated kinase 2 activation.
Cancer Res. 61:4222–4228. 2001.PubMed/NCBI
|
|
24
|
Takai E, Tsukimoto M, Harada H, Sawada K,
Moriyama Y and Kojima S: Autocrine regulation of TGF-β1-induced
cell migration by exocytosis of ATP and activation of P2 receptors
in human lung cancer cells. J Cell Sci. 125:5051–5060. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hong SH, Kim GY, Chang YC, Moon SK, Kim WJ
and Choi YH: Bufalin prevents the migration and invasion of T24
bladder carcinoma cells through the inactivation of matrix
metalloproteinases and modulation of tight junctions. Int J Oncol.
42:277–286. 2013.
|
|
26
|
Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang
Z, Yang CJ, Yuan L and Ouyang G: Twist2 contributes to breast
cancer progression by promoting an epithelial-mesenchymal
transition and cancer stem-like cell self-renewal. Oncogene.
30:4707–4720. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bolós V, Peinado H, Pérez-Moreno MA, Fraga
MF, Esteller M and Cano A: The transcription factor Slug represses
E-cadherin expression and induces epithelial to mesenchymal
transitions: A comparison with Snail and E47 repressors. J Cell
Sci. 116:499–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valcourt U, Kowanetz M, Niimi H, Heldin CH
and Moustakas A: TGF-β and the Smad signaling pathway support
transcriptomic reprogramming during epithelial-mesenchymal cell
transition. Mol Biol Cell. 16:1987–2002. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brandl M, Seidler B, Haller F, Adamski J,
Schmid RM, Saur D and Schneider G: IKK(α) controls canonical
TGF(β)-SMAD signaling to regulate genes expressing SNAIL and SLUG
during EMT in panc1 cells. J Cell Sci. 123:4231–4239. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsuji T, Ibaragi S, Shima K, Hu MG,
Katsurano M, Sasaki A and Hu GF: Epithelial-mesenchymal transition
induced by growth suppressor p12CDK2-AP1 promotes tumor cell local
invasion but suppresses distant colony growth. Cancer Res.
68:10377–10386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katoh M and Katoh M: Integrative genomic
analyses of ZEB2: Transcriptional regulation of ZEB2 based on
SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB. Int J Oncol.
34:1737–1742. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang S, Hölzel M, Knijnenburg T,
Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C,
Prahallad A, et al: MED12 controls the response to multiple cancer
drugs through regulation of TGF-β receptor signaling. Cell.
151:937–950. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Zhou F, García de Vinuesa A, de
Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A,
et al: TRAF4 promotes TGF-β receptor signaling and drives breast
cancer metastasis. Mol Cell. 51:559–572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eichhorn PJ, Rodón L, Gonzàlez-Juncà A,
Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A,
et al: USP15 stabilizes TGF-β receptor I and promotes oncogenesis
through the activation of TGF-β signaling in glioblastoma. Nat Med.
18:429–435. 2012. View
Article : Google Scholar : PubMed/NCBI
|
